Comparative Analysis of SLCO1B1 Gene Polymorphisms in Dyslipidemic and Normolipidemic Patients with Type 2 Diabetes Mellitus Residing at High Altitude Authors: Yong-Hong Ma, Zong-Hong Ji, Chun-Na Han, Sheng-Hua Ma, Jin-Lan Ma, Rui-Xia Zhang, Zhuo-Ma Ni-Yang, Zhi-Xi Zhao, Qi-Fu Zhang Published: 2026 ABSTRACT AbstractObjectiveTo examine the association between SLCO1B1 gene polymorphisms and blood lipid metabolism in Tibetan patients with type 2 diabetes mellitus (T2DM) in Yushu, Qinghai, China.MethodsA cross-sectional study enrolled 156 Tibetan T2DM patients (78 normolipidemic and 78 dyslipidemic) admitted to Yushu People’s Hospital between September 2022 and December 2023. SLCO1B1 521T>C and 388A>G polymorphisms were genotyped using PCR-RFLP.ResultsThe 521TC genotype frequency was significantly higher in the dyslipidemia group (30.8% vs. 14.1%, p < 0.05), with elevated triglycerides, total cholesterol, and low-density lipoprotein cholesterol (p < 0.01). Multivariate regression confirmed positive associations. The 388AG and 388GG genotypes were associated with elevated triglycerides (p < 0.05).ConclusionSLCO1B1 521T>C and 388A>G polymorphisms are significantly associated with dyslipidemia in this high-altitude Tibetan T2DM population, with 521T>C showing stronger predictive potential.Keywords: diabetes mellitus, gene polymorphism, high-altitude region, lipid metabolism, SLCO1B1 Introduction Diabetes mellitus constitutes a major global health challenge, with type 2 diabetes mellitus (T2DM) accounting for approximately 90% of all diagnosed cases. Populations residing in high-altitude regions are exposed to complex environmental conditions, including heightened ultraviolet radiation, reduced oxygen availability, and low temperatures. Evidence indicates that residents living at elevations above 3200 meters are at increased risk for cardiovascular and cerebrovascular diseases, accompanied by increased prevalence of hyperglycemia and hyperlipidemia. T2DM is driven by insulin resistance and progressive β-cell failure, creating a metabolic milieu that disrupts lipid homeostasis and significantly elevates cardiovascular risk. The SLCO1B1 gene, which regulates the hepatic uptake of statins and endogenous compounds like bile acids, plays a critical role in both lipid metabolism and pharmacogenetics; thus, its polymorphisms may modulate dyslipidemia in diabetic patients. Furthermore, in high-altitude environments characterized by chronic hypoxia, alterations in lipid metabolism and increased oxidative stress may interact with these genetic and diabetic factors, potentially exacerbating the underlying pathophysiology. Genetic polymorphisms in the SLCO1B1 gene, which encodes the hepatic transporter organic anion transporting polypeptide 1B1 (OATP1B1), have been reported to influence blood lipid levels among individuals with T2DM. Among these variants, 521T>C (rs4149056) and 388A>G (rs2306283) are the most extensively studied, with reported differences in allele frequencies across ethnic populations.1–3 However, few studies have directly examined the association between SLCO1B1 polymorphisms and T2DM, particularly in the context of lipid metabolism regulation among individuals with T2DM living in high-altitude, hypoxic environments. High-altitude hypoxia profoundly influences the reprogramming of cellular energy metabolism. The stabilization of Hypoxia-Inducible Factors (HIFs) regulates downstream genes involved in glycolysis and fatty acid metabolism, inhibiting oxidative phosphorylation and altering the balance between fatty acid synthesis and oxidation. In this context, investigating the interaction between specific genetic polymorphisms and environmental hypoxic stress is crucial for understanding the unique metabolic adaptation mechanisms in the Tibetan population. While the association between SLCO1B1 polymorphisms and dyslipidemia has been established in lowland Asian populations, data regarding the impact of these genetic variations on lipid profiles under chronic high-altitude hypoxic conditions remain scarce. To the best of our knowledge, this is the first study to specifically investigate the genetic determinants of lipid metabolism among Tibetan patients with type 2 diabetes mellitus living at high altitudes. We selected the SLCO1B1 521T>C and 388A>G polymorphisms because they are the most functionally significant variants known to alter the transport activity of OATP1B1 for endogenous substrates, such as bile acids, which are critical regulators of lipid homeostasis. Furthermore, these specific loci exhibit distinct ethnic frequency distributions and have been rarely investigated in the context of high-altitude hypoxic environments, making them ideal markers for this study. The present study aimed to evaluate the association between the SLCO1B1 521T>C and 388A>G polymorphisms and blood lipid metabolism in Tibetan individuals with T2DM residing at high altitude. Materials and Methods Study Population A cross-sectional study was conducted involving patients with T2DM who were hospitalized in the Department of Internal Medicine at Yushu People’s Hospital between September 2022 and December 2023. Ethnic background was confirmed through follow-up interviews, with all participants reporting Tibetan parentage on both the maternal and paternal sides. Based on a sample size calculation assuming a detection rate of 10%, a significance level (α) of 0.05, and a statistical power (1–β) of 80%, the required sample size was estimated to be approximately 78 participants per group. A total of 156 eligible patients with T2DM who had not received lipid-lowering therapy were consecutively enrolled using a sequential sampling method. Participants were stratified into two groups according to lipid profile results obtained at the time of enrollment, following the diagnostic criteria defined in the Guidelines for the Prevention and Treatment of Dyslipidemia in Chinese Adults (2016 Revision).4 The first 78 patients with normal lipid levels were assigned to the T2DM normolipidemic group, and the subsequent 78 patients with dyslipidemia were assigned to the T2DM with dyslipidemia group, ensuring balanced sample sizes to ensure adequate statistical power. Dyslipidemia was defined by the presence of one or more of the following abnormalities: hypercholesterolemia (total cholesterol [TC] ≥6.2 mmol/L), hypertriglyceridemia (triglycerides [TG] ≥2.3 mmol/L), low high-density lipoprotein cholesterol (HDL-C) (≤1.0 mmol/L in males and ≤1.3 mmol/L in females), or low-density lipoprotein cholesterol (LDL-C) (≥4.1 mmol/L). All participants met the diagnostic criteria for T2DM as outlined in the Guideline for the Prevention and Treatment of Type 2 Diabetes Mellitus in China (2020 edition).5 Exclusion criteria included the presence of other forms of diabetes, acute diabetic complications, severe cognitive impairment, psychiatric disorders, malignant tumors, documented metabolic disorders, and current use of lipid-lowering agents. None of the enrolled participants were biologically related. Ethical approval for the study was obtained from the Ethics Committee of the Affiliated Hospital of Qinghai University (Approval No. P-SL-2022108). The unrelatedness of participants was confirmed through self-reported family history obtained via a standardized questionnaire during the recruitment interview. Data Collection Demographic and clinical data, including age, sex, and duration of T2DM, were documented for each participant. Anthropometric measurements comprised height, body weight, and waist circumference, and body mass index (BMI) was calculated. Blood lipid parameters, including TG, TC, HDL-C, and LDL-C, were measured using enzymatic methods on an automated biochemical analyzer. Glycemic parameters, including glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), 2-hour postprandial glucose (2hPG), and fasting insulin (F-Ins), were also assessed. The homeostasis model assessment (HOMA) was applied to calculate the insulin resistance index (HOMA-IR) and β-cell secretion index (HOMA-β). Extraction of Genomic DNA from Peripheral Blood Leukocytes Following a 12-hour fast, 1 mL of antecubital venous blood was collected from each participant in the early morning and placed into EDTA-anticoagulated tubes and store in −80°C. Genomic DNA was extracted from 2 μL of whole blood using a commercially available human blood DNA extraction kit (Shanghai Sangon Health Medical Laboratory Co., Ltd., Shanghai, China), in accordance with the manufacturer’s protocol. Detection of SLCO1B1 Gene Polymorphisms Genotyping of the SLCO1B1 521T>C (rs4149056) and 388A>G (rs2306283) polymorphisms was performed using polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) method. Primer sequences were designed by Sangon Biotech (Shanghai) Co., Ltd. The primer pair for 388A>G was: forward 5’-CTGTGTTGTTAATGGGCGAACTGTG-3’ and reverse 5’-ACACATGCTGGGAAATTGACAGAAA-3’, producing a 334 bp amplicon. For 521T>C, the forward primer was 5’-ATAAATGAGAGTTCCCCTGCAAAAG-3’ and the reverse primer was 5’-CAAGAATGCATGGTTCTTATTCACC-3’, yielding a 285 bp amplicon. Each 50 μL PCR reaction mixture contained 2 μL template DNA, 0.5 μL Taq polymerase (Takara Bio Inc., Shiga, Japan), 5 μL 10× PCR buffer, 4 μL dNTP mixture (2.5 mM), 1 μL of each primer (10 μM), and 36.5 μL double-distilled water. Thermocycling conditions included an initial denaturation at 95 °C for 5 minutes; followed by 35 cycles of denaturation at 95 °C for 30 seconds, annealing at 60 °C (388A>G locus) or 58 °C (521T>C locus) for 30 seconds, and extension at 72 °C for 45 seconds; with a final extension at 72 °C for 10 minutes. For the SLCO1B1 388A>G (rs2306283) locus, the PCR amplification yielded a 334 bp fragment. Following digestion with the Rsa I restriction endonuclease, the AA homozygous genotype displayed a single band at 334 bp, the AG heterozygous genotype produced three bands at 334 bp, 207 bp, and 127 bp, and the GG homozygous genotype showed two bands at 207 bp and 127 bp. For the SLCO1B1 521T>C (rs4149056) locus, the PCR amplification yielded a 285 bp fragment. Following digestion with the Bst UI restriction endonuclease, the TT homozygous genotype displayed a single band at 285 bp, the TC heterozygous genotype produced three bands at 285 bp, 168 bp, and 117 bp, and the CC homozygous genotype showed two bands at 168 bp and 117 bp. PCR products were verified via 2% agarose gel electrophoresis and purified using ethanol precipitation. Restriction digestion was performed using BstUI for 521T>C at 37 °C for 16 hours and RsaI (Sangon Biotech (Shanghai) Co., Ltd.) for 388A>G. Digested fragments were separated by 2.5% agarose gel electrophoresis, stained with ethidium bromide, visualized under ultraviolet light, and documented using a gel imaging system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Ten percent of samples were randomly selected for direct sequencing verification (Sangon Biotech (Shanghai) Co., Ltd)., with sequencing results demonstrating 100% concordance with those obtained by gel electrophoresis. Genotype distributions for the SLCO1B1 521T>C and 388A>G polymorphisms were assessed for Hardy–Weinberg equilibrium. Statistical Analysis All statistical analyses were conducted using SPSS Statistics, version 25.0 (IBM Corp., Armonk, NY, USA). Normally distributed continuous variables were expressed as mean ± standard deviation () and compared between groups using the independent-samples t-test. Non-normally distributed continuous variables were reported as median with interquartile range [M (P25, P75)] and compared using the Mann–Whitney U-test. Categorical variables were expressed as frequencies or percentages and compared using the chi-squared test or Fisher’s exact test, as appropriate. Multiple linear regression analysis was performed to assess associations between SLCO1B1 gene polymorphisms and lipid and glycemic parameters (Covariates included age, sex, body mass index (BMI), waist circumference, blood pressure, duration of diabetes, vascular complications, fasting blood glucose, 2-hour postprandial blood glucose, glycated hemoglobin (HbA1c), fasting insulin, HOMA-IR, and HOMA-β). Owing to the cross-sectional nature of the study, the statistical analyses were limited to identifying associations, without inferring causality. A two-tailed p value < 0.05 was considered statistically significant. Results Comparison of General Characteristics and Biochemical Parameters Between Groups No statistically significant differences were observed between the two groups in terms of age or sex distribution (p > 0.05). BMI and blood pressure levels were significantly higher in the dyslipidemia group than in the normolipidemic group (p < 0.01). Serum levels of TG, TC, and LDL-C were significantly elevated in the dyslipidemia group, whereas HDL-C levels were significantly lower (p < 0.001). The prevalence of vascular complications was also greater in the dyslipidemia group (69.2%) than in the normolipidemic group (39.7%) (p < 0.001, Table 1). These findings collectively indicate that the dyslipidemia group exhibited a significantly more adverse metabolic profile and a higher burden of vascular complications compared to the normolipidemic group. Table 1Comparison of General Characteristics and Biochemical Parameters Between the Normolipidemic and Dyslipidemia GroupsVariableNormal-Lipid Group (n=78)Dyslipidemia Group (n=78)t/Z/χ2p-valueSex (male/female)46(59.0)/32(41.0)42(53.8)/36(46.2)0.420.518Age (years)47.8±13.250.4±12.7−1.280.203BMI (kg/m2)24.9±4.526.8±4.2−2.810.006Systolic blood pressure (mmHg)114.2±15.6122.7±18.3−3.190.002Diastolic blood pressure (mmHg)75.8±10.481.2±11.8−3.090.002TG (mmol/L)1.38(1.12,1.74)3.42(2.56,4.91)*−8.74<0.001TC (mmol/L)3.97±0.725.51±1.18*−9.57<0.001LDL-C (mmol/L)2.64(2.28,3.21)4.02(3.41,5.13)*−7.65<0.001HDL-C (mmol/L)1.17(1.03,1.28)0.89(0.76,1.02)*−6.23<0.001FPG (mmol/L)8.49(7.76,9.67)11.23(9.85,12.91)*−6.47<0.001HbA1c (%)8.97±3.1210.68±3.45*−3.280.0012hPG (mmol/L)13.42±4.3817.15±5.62*−4.71<0.001HOMA-IR2.98(1.89,4.52)5.23(3.44,7.86)*−5.12<0.001HOMA-β29.34(15.67,47.21)21.78(12.89,36.45)*−2.380.017Vascular complications31(39.7)54(69.2)*13.67<0.001Note: *p < 0.05 indicates statistical significance compared with the normolipidemic group. Comparison of General Characteristics and Biochemical Parameters Between the Normolipidemic and Dyslipidemia Groups Note: *p < 0.05 indicates statistical significance compared with the normolipidemic group. Distribution of SLCO1B1 Gene Polymorphisms and Hardy–Weinberg Equilibrium Testing For the 521T>C locus, the χ2 values were 0.27 in the normolipidemic group and 1.82 in the dyslipidemia group, with corresponding p values of 0.603 and 0.177, respectively. For the 388A>G locus, the χ2 values were 0.45 in the normolipidemic group and 0.89 in the dyslipidemia group, with p values of 0.798 and 0.641, respectively. Genotype frequencies at both loci conformed to Hardy–Weinberg equilibrium in each group (p > 0.05). The frequency of the TC genotype at the 521T>C locus was significantly higher in the dyslipidemia group than in the normolipidemic group (30.8% vs 14.1%, χ2 = 5.94, p = 0.015). Genotype distribution at the 388A>G locus did not differ significantly between the two groups (χ2 = 0.69, p = 0.708). Notably, no participants were homozygous for the CC genotype at the 521T>C locus, consistent with prior studies reporting a low prevalence of this genotype (approximately 0.5–1%) in Chinese populations (Table 2). These results indicate a significant association between the TC genotype at the 521T>C locus and dyslipidemia in this cohort, whereas no such association was found for the 388A>G locus, with all genotype distributions meeting Hardy-Weinberg equilibrium expectations. Table 2Distribution of SLCO1B1 Gene Polymorphisms in the Normolipidemic and Dyslipidemia GroupsGenetic LocusNormolipidemic Group (n=78)Dyslipidemia Group (n=78)χ2P521T>CTT67(85.9)54(69.2)5.940.015TC11(14.1)24(30.8)*CC0(0.0)0(0.0)388A>GAA9(11.5)7(9.0)0.690.708AG24(30.8)27(34.6)GG45(57.7)44(56.4)Note: *p < 0.05 indicates a statistically significant difference between groups. Distribution of SLCO1B1 Gene Polymorphisms in the Normolipidemic and Dyslipidemia Groups Note: *p < 0.05 indicates a statistically significant difference between groups. Associations Between SLCO1B1 Gene Polymorphisms and Clinical Parameters At the 521T>C locus, patients with the TC genotype exhibited significantly higher levels of TG, TC, LDL-C, and blood pressure compared with those carrying the TT genotype (p < 0.01). HDL-C levels were significantly lower among TC genotype carriers (p < 0.01). No significant differences in insulin resistance, as measured by HOMA-IR, were observed between the genotypes (p = 0.278). At the 388A>G locus, patients with either the AG or GG genotype had significantly higher TG levels than those with the AA genotype (p < 0.01). Other metabolic parameters did not differ significantly across genotypes (Table 3). These findings demonstrate that the TC genotype at the 521T>C locus is associated with a broader adverse metabolic profile, including dyslipidemia and hypertension, whereas the 388A>G locus appears to influence only triglyceride metabolism. Table 3Comparison of Clinical Parameters Among Different SLCO1B1 GenotypesVariable521T>CP388A>GPTT (n=121)TC (n=35)AA (n=16)AG (n=51)GG (n=89)TG(mmol/L)2.09±1.524.18±1.89*<0.0012.03±0.763.71±1.48*3.52±1.41*0.006TC (mmol/L)4.48±1.025.38±1.31*<0.0014.12±0.694.91±1.224.67±1.150.089LDL-C (mmol/L)3.02±0.944.15±1.42*<0.0012.94±0.783.48±1.183.31±1.120.312HDL-C (mmol/L)1.06±0.240.94±0.22*0.0091.09±0.261.01±0.231.02±0.240.576Systolic blood pressure (mmHg)116.3±16.2125.8±18.7*0.004113.8±14.9119.2±17.1118.7±16.40.534Diastolic blood pressure (mmHg)76.8±10.782.9±12.3*0.00675.4±9.778.9±11.279.1±11.60.621HOMA-IR3.87±2.944.52±3.210.2783.74±2.414.18±3.063.91±2.890.827HOMA-β26.43±14.8222.15±12.67*0.12528.91±16.2324.78±13.4525.34±14.890.698Notes: *p < 0.05 indicates a statistically significant difference compared with the TT genotype (for 521T>C) or AA genotype (for 388A>G). Comparison of Clinical Parameters Among Different SLCO1B1 Genotypes Notes: *p < 0.05 indicates a statistically significant difference compared with the TT genotype (for 521T>C) or AA genotype (for 388A>G). Multivariate Linear Regression Analysis of Factors Associated with Lipid Metabolism in T2DM Multivariate linear regression analysis demonstrated that the TC genotype at the SLCO1B1 521T>C locus, as well as the AG and GG genotypes at the 388A>G locus, were significantly and positively associated with elevated TG levels (p < 0.05). Additionally, the TC genotype at the 521T>C locus was independently associated with increased TC and LDL-C levels (p < 0.01 for both). In contrast, the AG genotype at the 388A>G locus showed no statistically significant association with TC or LDL-C levels (p > 0.05) (Table 4). These results indicate that while both SLCO1B1 polymorphisms are associated with hypertriglyceridemia, only the 521T>C locus (specifically the TC genotype) demonstrates an independent association with elevations in total cholesterol and LDL-C levels. Table 4Multiple Linear Regression Analysis of Factors Associated with Lipid MetabolismDependent VariableIndependent VariableβSEtP95% CITG521TC0.487*0.4233.956<0.0010.528~2.087388AG0.392*0.3872.8450.0070.394~1.742388GG0.368*0.3712.6340.0120.267~1.598TC521TC0.356*0.3122.7890.0080.198~1.323388AG0.2640.2781.8970.064−0.038~1.156LDL-C521TC0.431*0.2983.4520.0010.289~1.421388AG0.2670.2632.0180.051−0.012~1.087Notes: *p < 0.05 indicates statistical significance. All models were adjusted for sex, age, BMI, blood pressure, and glycemic parameters. Multiple Linear Regression Analysis of Factors Associated with Lipid Metabolism Notes: *p < 0.05 indicates statistical significance. All models were adjusted for sex, age, BMI, blood pressure, and glycemic parameters. Discussion This study suggests that SLCO1B1 variants may predispose individuals to dyslipidemia by impairing the hepatic uptake of lipids, thereby reducing the clearance of circulating TG, TC, and LDL-C. While our findings align with previous reports linking the 521T>C polymorphism to adverse metabolic profiles, the distinct impact of the 388A>G locus on isolated hypertriglyceridemia and the potential influence of high-altitude hypoxia on lipid metabolism warrant further investigation. These results imply that SLCO1B1 genotyping could be a valuable tool for predicting dyslipidemia risk and optimizing statin therapy, particularly in high-altitude diabetic populations where altered pharmacokinetics may affect drug efficacy and toxicity. Consequently, incorporating this genetic information into clinical practice may contribute significantly to the advancement of precision medicine in cardiometabolic health. The present study identified significant associations between SLCO1B1 gene polymorphisms and lipid metabolism in this high-altitude Tibetan cohort, indicating that the metabolic impact of specific genetic variants may be amplified under extreme environmental conditions. The SLCO1B1 gene encodes the hepatic transporter OATP1B1, which plays a critical role in bile acid transport and hepatic lipid regulation. The 521T>C polymorphism is known to reduce transporter activity by approximately 50% and has been associated with mild to moderate dyslipidemia in low-altitude populations. The more severe dyslipidemic phenotype observed in the current study suggests that chronic hypoxia at high-altitude may influence hepatic metabolic regulation, mitochondrial function, and energy balance, thereby producing synergistic effects with predisposing genetic variants. Individuals carrying the heterozygous TC genotype at the 521T>C locus exhibited dyslipidemia in the absence of insulin resistance. This observation appears to diverge from the conventional model of metabolic syndrome, which typically describes a strong association between dyslipidemia and insulin resistance, suggesting that this relationship may be more nuanced in high-altitude environments. It is possible that during high-altitude adaptation, distinct metabolic regulatory networks are established that can modulate glucose and lipid metabolism through partially separate molecular pathways.6–8 Potential mechanisms underlying this metabolic dissociation may involve differential activation of the HIF signaling pathway, the AMPK energy-sensing system, and transcription regulating lipid metabolism.9–12 These findings underscore the need for further mechanistic studies is essential for the development of precision therapeutic strategies for individuals with T2DM residing at high altitude. The observed selective association between the 388A>G polymorphism and triglyceride levels provides additional insights into the functional specificity of OATP1B1. The differential effects of individual SLCO1B1 variants on lipid subtypes suggest that the transporter may contain distinct functional domains responsible for substrate-specific activity. This concept of domain-specific transport has important implications for therapeutic development, including the design of small-molecule modulators targeting specific domains of OATP1B1 to achieve selective lipid regulation. The clinical translational value of this study lies in its contribution to the development of genotype-based risk stratification strategies for populations residing at high-altitude. Identification of the SLCO1B1 521T>C variant may serve as an adjunctive tool for optimizing lipid management in individuals with T2DM in this setting. Detection of this polymorphism could assist in identifying individuals at elevated risk for dyslipidemia who may benefit from intensified interventions. In high-altitude areas, where healthcare resources are limited, genotype-based screening strategies may enhance resource allocation and facilitate precision prevention efforts. As the cost of genotyping continues to decline, the integration of 521T>C variant testing into primary healthcare settings is becoming increasingly feasible.13–17 Future health economic evaluations are needed to determine the cost-effectiveness of genotype-guided individualized management strategies in these populations. The CC homozygous genotype at the SLCO1B1 521T>C locus was not detected in any of the 156 Tibetan participants, yielding a genotype frequency of 0%. This finding is consistent with previous studies in Chinese populations, which have reported an extremely low detection rate of the CC genotype (approximately 0.5–1%) in the general Chinese population and its particularly rare occurrence in ethnic minority groups such as Tibetans. The absence of the CC genotype may be attributable to the unique genetic background and population genetic structure of highland Tibetans, as well as the relatively limited sample size of the present study. Given that the 521T>C polymorphism significantly reduces the transport activity of organic anion-transporting polypeptide 1B1 (OATP1B1), the lack of CC homozygotes in our cohort suggests that the TC heterozygous genotype alone is sufficient to confer a significant risk of dyslipidemia in highland Tibetan patients with type 2 diabetes. Further large-scale studies are warranted to clarify the distribution characteristics of the CC genotype in this population and its potential metabolic implications. This study has several limitations. First, the cross-sectional design precludes causal inference regarding the relationships between SLCO1B1 gene polymorphisms and dyslipidemia. Second, the relatively modest sample size may have limited statistical power, particularly for subgroup analyses. Third, the use of sequential enrollment based on presentation order may have introduced selection bias, potentially limiting the generalizability of the findings. The absence of a low-altitude control group further limited the ability to isolate the specific contributions of high-altitude environmental exposure to gene–environment–disease interactions. And this study did not account for potential confounders such as smoking status, alcohol intake, physical activity, dietary habits, and non-lipid-lowering medication history, which may influence lipid metabolism. These unmeasured variables limit our ability to fully isolate the specific impact of SLCO1B1 polymorphisms on the observed lipid profiles. Additionally, the lack of long-term follow-up precluded assessment of associations between genotypes and cardiovascular outcomes. Furthermore, the current study design utilized a T2D patient cohort without including a healthy non-diabetic control group, which limits our ability to determine whether the observed associations are specific to the diabetic state or represent general metabolic adaptations. Conclusion This cross-sectional study identified significant associations between SLCO1B1 521T>C and 388A>G polymorphisms and alterations in blood lipid levels among Tibetan individuals with T2DM residing at high altitude. In particular, the heterozygous TC genotype at the 521T>C locus demonstrated a strong association with dyslipidemia and may serve as a potential biomarker for lipid risk stratification in this population. However, due to the inherent limitations of cross-sectional research, causality cannot be established. Further large-scale prospective cohort studies and randomized controlled trials are required to further evaluate the predictive value and clinical utility of these polymorphisms in guiding lipid management strategies for individuals with T2DM in high-altitude regions. Funding Statement Young and middle-aged Scientific Research Project of the Affiliated Hospital of Qinghai University (No.: ASRF-2022-YB-03). Qinghai Provincial Science and Technology Department project (Project name: Qinghai Clinical Medical Research Center for Metabolic Diseases; Project Number: 2025-SF-L01). Abbreviations T2DM, Type 2 Diabetes Mellitus; SLCO1B1, Solute Carrier Organic Anion Transporter Family Member 1B1; TC, Total Cholesterol; HDL-C, High-Density Lipoprotein Cholesterol; LDL-C, Low-Density Lipoprotein Cholesterol; FPG, Fasting Plasma Glucose; 2hPG, 2-hour Postprandial Plasma Glucose; F-Ins, Fasting Insulin; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; HOMA-β, Homeostatic Model Assessment of Beta-cell function; PCR-RFLP, Polymerase Chain Reaction - Restriction Fragment Length Polymorphism. Ethics Approval and Consent to Participate This study was conducted in accordance with the declaration of Helsinki. This study was conducted with approval from the Ethics Committee of Qinghai University Affiliated Hospital (P-SL-2022108). A written informed consent was obtained from all participants. Author contributions Conception and design of the research: Yong-Hong Ma, Qi-Fu Zhang, Rui-Xia Zhang, Sheng-Hua Ma. Acquisition of data: Zong-Hong Ji, Qi-Fu Zhang, Chun-Na Han, Zhuo-Ma-Ni-Yang, Zhi-Xi Zhao. Analysis and interpretation of the data: Qi-Fu Zhang, Zong-Hong Ji, Chun-Na Han, Jin-Lan Ma, Zhuo-Ma-Ni-Yang, Zhi-Xi Zhao Statistical analysis: Yong-Hong Ma, Qi-Fu Zhang, Rui-Xia Zhang,Sheng-Hua Ma, Jin-Lan Ma. Obtaining financing: Yong-Hong Ma, Rui-Xia Zhang, Qi-Fu Zhang. Writing of the manuscript: Zong-Hong Ji, Yong-Hong Ma, Qi-Fu Zhang. Critical revision of the manuscript for intellectual content: Yong-Hong Ma, Qi-Fu Zhang. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors report no conflicts of interest in this work. References